The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer

• Status: Unknown status
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Pancreatic cancer is a very poor prognosis and has a high mortality rate. The clinical results have improved somewhat with the combination therapy of chemotherapy as the first-line treatment. However, effective secondary chemotherapy after these first-line treatment failures is limited. Recently, FOLFIRINOX has been used in patients with locally advanced or metastatic pancreatic cancer who have good performance in Korea. Gemcitabine + nab-paclitaxel (GnP) as a second-line treatment after FOLFIRINOX may be expected to be considerable. The aim of this study was to evaluate the efficacy of GnP as a second-line treatment after failed FOLFIRINOX treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Albumin-Bound Paclitaxel; Gemcitabine; Paclitaxel

Criteria

1. Inclusion criteria

1. Patient whose age is 20 years or older

2. ECOG Performance Status 0-2

3. Pathologically confirmed pancreatic adenocarcinoma

4. Patients with locally advanced or distant metastasis status

5. Patients who had undergone primary chemotherapy with previous FOLFIRINOX and whose disease progress was confirmed

6. Patients whose consent was obtained (non-insurance agreement)

2. Exclusion Criteria

1. Those who can not obtain consent

2. Those who refuse chemotherapy

3. ECOG Performance Status 3 or higher

4. Multiple organ failure is accompanied

5. Severe comorbidities other than cancer that do not expect a sufficient survival period over 1 month

6. Allergy to the test drug